Target intelligence / Profile preview

FAT atypical cadherin 2 (FAT2)

Target
FAT2
Molecular classification
Cadherin superfamily (cadherin-type repeats, cell adhesion molecule), Single-pass transmembrane protein, Other (contains EGF-like repeats, laminin G domains)
01

Overview

FAT atypical cadherin 2 is a giant cell surface protein belonging to the cadherin superfamily, containing 34 tandem cadherin repeats, two epidermal growth factor (EGF)-like repeats, and one laminin G domain[2][3][7]. FAT2 acts as a cell adhesion molecule implicated in the regulation of cell proliferation, planar cell polarity, tissue morphogenesis, and development, notably in the cerebellum[2][3][4]. FAT2’s role includes organizing parallel fibers in granule cells during cerebellar development and regulating cell migration[3]. Pathologically, mutations or loss of FAT2 have been linked to tumorigenesis through disruption of the Hippo pathway and are associated with neurological disorders such as spinocerebellar ataxia[1][3]. FAT2’s paralog, FAT1, and related family members share overlapping functions in cytoskeletal organization, adhesion, and developmental processes[3][4]. Although not currently a druggable target, its involvement in cell signaling and cancer makes it a candidate for future therapeutic exploration[2][3].

Other names
CDHF8CDHR9HFAT2MEGF1SCA45
02

Mechanism of action

Not established for drugs; therapeutics would theoretically modulate cell adhesion, signaling or proliferation via FAT2 activity.

03

Biological functions

Cell adhesionRegulation of cell migration, proliferation, tissue developmentPlanar cell polarity regulationCerebellum developmentOrganization of actin cytoskeleton (by homology and functional domains)
04

Disease associations

Cancer (mutations associated with tumor progression and defective Hippo signaling pathway)Spinocerebellar ataxia 45Skin squamous cell carcinomaOther possible neurological disorders
05

Safety considerations

Modulation may influence cell proliferation and migration, affecting developmental and oncogenic pathwaysRisk of off-target effects due to broad expression and functional redundancy with other cadherins.
06

Interacting drugs

None clearly established in current literature and databases
07

Biomarkers

There is emerging evidence of FAT2 expression as a potential biomarker for cerebellar disease and certain cancers

Beyond the preview

Go deeper on FAT atypical cadherin 2 (FAT2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAT atypical cadherin 2 (FAT2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call